|
Jul 22
|
Why Sarepta's halted drug Elevidys is an issue for investors
|
|
Jul 22
|
Sarepta Faces Fresh Setback. Why Now’s Not the Time to Buy the Stock.
|
|
Jul 22
|
Sarepta shares slide again as drugmaker bows to FDA pressure to pause gene therapy
|
|
Jul 22
|
Sarepta falls after gene therapy maker pauses Elevidys shipments in US
|
|
Jul 22
|
Netflix downgraded, Intel initiated: Wall Street's top analyst calls
|
|
Jul 22
|
SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny
|
|
Jul 22
|
Morning Movers: Cleveland-Cliffs rallies after second quarter earnings release
|
|
Jul 22
|
Sarepta halts Elevidys shipments following FDA pressure
|
|
Jul 21
|
Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in the U.S.
|
|
Jul 21
|
Sarepta under pressure: FDA requests halt of Elevidys shipments
|
|
Jul 21
|
These Stocks Moved the Most Today: Sarepta, Verizon, Cleveland-Cliffs, Block, Tesla, DJT, Bruker, and More
|
|
Jul 21
|
Sarepta's 'Unprecedented Times' Continue As Company Rebukes The FDA
|
|
Jul 21
|
Sarepta Therapeutics laying off dozens in Ohio, won't comply with FDA request to halt therapy
|
|
Jul 21
|
Navitas skyrockets, Dollar Tree upgraded, Sarepta & FDA
|
|
Jul 21
|
Sarepta refuses to pull gene therapy despite FDA request
|
|
Jul 21
|
Top Stock Movers Now: Verizon, Cleveland-Cliffs, Newmont, Sarepta, and More
|
|
Jul 18
|
Sarepta (SRPT) Jumps Nearly 20% on Corporate Restructuring
|
|
Jul 18
|
Sarepta Therapeutics Crashes After A Third Gene Therapy Patient Dies
|
|
Jul 18
|
Stocks See Support from Dovish Fed Official Comment
|
|
Jul 18
|
Sarepta Therapeutics Stock Tumbles on Report of Third Death in Clinical Trial
|